Press Releases

Virtual partnering event launched to accelerate partnerships in the life sciences industry to fight against COVID-19

COVID-19 Virtual Partnering is a unique and free-to-attend virtual event taking place on 20 April – 06 May. The initiative is backed by a consortium of biotech clusters…

Evaluate Ltd. acquires Black Swan Analysis, accelerating the growth strategy of the business and further optimising the product portfolio

Evaluate Ltd., the leading provider of commercial intelligence and predictive analytics to the pharmaceutical industry, is delighted to announce today that it has…

Evaluate Vantage 2019 Review: Standout year for pharma, anchored by strong fourth quarter markets and dealmaking

Stock market gains and dealmaking activity in Q4 clinched the biopharma sector’s strong performance in 2019 – a stark reversal of the declines seen in the final months of…

Evaluate Vantage 2020 Preview: Strong sales and product launches set the stage for biopharma growth, but underlying market concerns exist

Oncology dominates the growth outlook for pharma; four of the eight drugs expected to add $1bn or more in new sales next year are for cancer, according to the Evaluate…

Evaluate Ltd. appoints Martyn Hindley as Chief Financial Officer

Evaluate Ltd., the leading provider of commercial data to the life sciences industry, is pleased to announce the appointment of Martyn Hindley as Chief Financial Officer,…

Evaluate Ltd. transforms pharma R&D risk assessment with launch of Product Specific PTRS

Breakthrough offering combines the power of machine learning with the transparency of Evaluate’s renowned analytical approach for the most accurate analysis of drug…

Evaluate Vantage Half-Year Review 2019: Pharma and medtech mega-deals mask drop in M&A activity

The report, published today, analyses stock and market performance, M&A and the financing landscape during the first half of 2019

Innovation and unmet need drive prescription drug sales to $1.18tr by 2024: new report from Evaluate Ltd

“EvaluatePharma® World Preview 2019, Outlook to 2024” explores growth drivers, growth brakes and top industry performers.

The “one and done” era for orphan drugs: Evaluate predicts 12% growth, driven by new technologies, but benefits go to big pharma

Orphan drug sales reach $242bn by 2024, according to EvaluatePharma® Orphan Drug Report 2019

Evaluate Ltd. appoints Deborah Kobewka as Chief Executive Officer